Development and validation of qPCR methods for nucleic acid biomarkers as a drug development tool : points to consider
Nucleic acid (NA) biomarkers play critical roles in drug development. However, the global regulatory guidelines for assessing quantification methods specific to NA biomarkers are limited. The validation of analytical methods is crucial for the use of biomarkers in clinical and post-marketing evaluations of drug efficacy and adverse reactions. Given that quantitative polymerase chain reaction (qPCR) and reverse transcription qPCR (RT-qPCR) methods are the gold standards for the quantification of NA biomarkers, the Biomarker Analytical Method Validation Study Group in Japan has discussed considerations and made recommendations for the development and validation of qPCR- and RT-qPCR-based analytical methods for endogenous NA biomarkers as drug development tools. This white paper aims to contribute to the global harmonization of NA biomarker assay validation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Bioanalysis - 15(2023), 17 vom: 16. Sept., Seite 1069-1081 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sun, Yuchen [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarkers |
|---|
| Anmerkungen: |
Date Completed 18.09.2023 Date Revised 18.09.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.4155/bio-2023-0071 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36083647X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36083647X | ||
| 003 | DE-627 | ||
| 005 | 20231226083850.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/bio-2023-0071 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1202.xml |
| 035 | |a (DE-627)NLM36083647X | ||
| 035 | |a (NLM)37584367 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sun, Yuchen |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Development and validation of qPCR methods for nucleic acid biomarkers as a drug development tool |b points to consider |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.09.2023 | ||
| 500 | |a Date Revised 18.09.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Nucleic acid (NA) biomarkers play critical roles in drug development. However, the global regulatory guidelines for assessing quantification methods specific to NA biomarkers are limited. The validation of analytical methods is crucial for the use of biomarkers in clinical and post-marketing evaluations of drug efficacy and adverse reactions. Given that quantitative polymerase chain reaction (qPCR) and reverse transcription qPCR (RT-qPCR) methods are the gold standards for the quantification of NA biomarkers, the Biomarker Analytical Method Validation Study Group in Japan has discussed considerations and made recommendations for the development and validation of qPCR- and RT-qPCR-based analytical methods for endogenous NA biomarkers as drug development tools. This white paper aims to contribute to the global harmonization of NA biomarker assay validation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a RT-qPCR | |
| 650 | 4 | |a method validation | |
| 650 | 4 | |a nucleic acid biomarkers | |
| 650 | 4 | |a qPCR | |
| 650 | 4 | |a regulatory submission | |
| 650 | 4 | |a study sample analysis | |
| 650 | 4 | |a white paper | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 700 | 1 | |a Nakamura, Takahiro |e verfasserin |4 aut | |
| 700 | 1 | |a Ohtsu, Yoshiaki |e verfasserin |4 aut | |
| 700 | 1 | |a Kakehi, Masaaki |e verfasserin |4 aut | |
| 700 | 1 | |a Danno, Noriyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Shimizu, Hiroyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Tanaka, Yoichi |e verfasserin |4 aut | |
| 700 | 1 | |a Serelli-Lee, Victoria |e verfasserin |4 aut | |
| 700 | 1 | |a Tanaka, Seiji |e verfasserin |4 aut | |
| 700 | 1 | |a Okayama, Takashige |e verfasserin |4 aut | |
| 700 | 1 | |a Suda, Yusuke |e verfasserin |4 aut | |
| 700 | 1 | |a Moriya, Yuu |e verfasserin |4 aut | |
| 700 | 1 | |a Hanada, Takeshi |e verfasserin |4 aut | |
| 700 | 1 | |a Saito, Yoshiro |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bioanalysis |d 2009 |g 15(2023), 17 vom: 16. Sept., Seite 1069-1081 |w (DE-627)NLM196969840 |x 1757-6199 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2023 |g number:17 |g day:16 |g month:09 |g pages:1069-1081 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4155/bio-2023-0071 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2023 |e 17 |b 16 |c 09 |h 1069-1081 | ||